Study Shows Castle Biosciences’ DecisionDx-UM is Highly Effective at Predicting Metastatic Risk in Patients with Eye Cancer

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced new study results of the Company’s DecisionDx-UM gene expression profile test, verifying that the assay is highly effective at identifying uveal melanoma tumors at high risk of metastasis. The results also confirmed the technical reliability of the test, which successfully classified 97% of uveal melanomas submitted for testing in this case se